Estrogen receptor α AF-2 mutation results in antagonist reversal and reveals tissue selective function of estrogen receptor modulators

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 36, 2011, Pages 14986-14991

  Arao, Yukitomo ^a   Hamilton, Katherine J ^a   Ray, Manas K ^b   Scott, Gregory ^b   Mishina, Yuji ^c   Korach, Kenneth S ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA AF 2; FULVESTRANT; LUTEINIZING HORMONE; PROLACTIN; TAMOXIFEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANOVULATION; ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE TARGETING; INFERTILITY; MOUSE; NEGATIVE FEEDBACK; NONHUMAN; OVARIECTOMY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AMINO ACID SUBSTITUTION; ANIMALS; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE KNOCK-IN TECHNIQUES; HELA CELLS; HUMANS; LUTEINIZING HORMONE; MALE; MAMMARY GLANDS, ANIMAL; MICE; MICE, KNOCKOUT; ORGAN SPECIFICITY; OVARY; PITUITARY GLAND; POINT MUTATION; PROTEIN STRUCTURE, TERTIARY; TAMOXIFEN; UTERUS;

MUS;

EID: 80052567302     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1109180108     Document Type: Article

References (34)

1. Brzozowski AM, et al. (1997) Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389:753-758. (Pubitemid 27458965)
2. Wu YL, et al. (2005) Structural basis for an unexpected mode of SERM-mediated ER antagonism. Mol Cell 18:413-424.
3. Danielian PS, White R, Lees JA, Parker MG (1992) Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors. EMBO J 11:1025-1033.
4. Valentine JE, Kalkhoven E, White R, Hoare S, Parker MG (2000) Mutations in the estrogen receptor ligand binding domain discriminate between hormone-dependent transactivation and transrepression. J Biol Chem 275:25322-25329.
5. Mahfoudi A, Roulet E, Dauvois S, Parker MG, Wahli W (1995) Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists. Proc Natl Acad Sci USA 92:4206-4210.
6. Ince BA, Zhuang Y, Wrenn CK, Shapiro DJ, Katzenellenbogen BS (1993) Powerful dominant negative mutants of the human estrogen receptor. J Biol Chem268:14026-14032. (Pubitemid 23195519)
7. Ince BA, Schodin DJ, Shapiro DJ, Katzenellenbogen BS (1995) Repression of endogenous estrogen receptor activity in MCF-7 human breast cancer cells by dominant negative estrogen receptors. Endocrinology 136:3194-3199.
8. Schodin DJ, Zhuang Y, Shapiro DJ, Katzenellenbogen BS (1995) Analysis of mechanisms that determine dominant negative estrogen receptor effectiveness. J Biol Chem 270:31163-31171. (Pubitemid 26012204)
9. Montano MM, Ekena K, Krueger KD, Keller AL, Katzenellenbogen BS (1996) Human estrogen receptor ligand activity inversion mutants: Receptors that interpret antiestrogens as estrogens and estrogens as antiestrogens and discriminate among different antiestrogens. Mol Endocrinol 10:230-242. (Pubitemid 26084369)
10. McDonnell DP (1999) The Molecular Pharmacology of SERMs. Trends Endocrinol Metab 10:301-311.
11. Smith CL, Nawaz Z, O'Malley BW (1997) Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol Endocrinol 11:657-666. (Pubitemid 27225293)
12. Berry M, Metzger D, Chambon P (1990) Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J 9:2811-2818.
13. Lubahn DB, et al. (1993) Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. Proc Natl Acad Sci USA 90:11162-11166. (Pubitemid 23354389)
14. Hewitt SC, et al. (2010) Biological and biochemical consequences of global deletion of exon 3 from the ER alpha gene. FASEB J 24:4660-4667.
15. Couse JF, Korach KS (1999) Estrogen receptor null mice: What have we learned and where will they lead us? Endocr Rev 20:358-417. (Pubitemid 30654784)
16. Jakacka M, et al. (2001) Estrogen receptor binding to DNA is not required for its activity through the nonclassical AP1 pathway. J Biol Chem 276:13615-13621.
17. Couse JF, Yates MM, Walker VR, Korach KS (2003) Characterization of the hypothalamic-pituitary-gonadal axis in estrogen receptor (ER) Null mice reveals hypergonadism and endocrine sex reversal in females lacking ERalpha but not ERbeta. Mol Endocrinol 17:1039-1053. (Pubitemid 36683712)
18. Jeong JW, et al. (2010) Foxa2 is essential for mouse endometrial gland development and fertility. Biol Reprod 83:396-403.
19. Lee MO, Liu Y, Zhang XK (1995) A retinoic acid response element that overlaps an estrogen response element mediates multihormonal sensitivity in transcriptional activation of the lactoferrin gene. Mol Cell Biol 15:4194-4207.
20. Hewitt SC, Li Y, Li L, Korach KS (2010) Estrogen-mediated regulation of Igf1 transcription and uterine growth involves direct binding of estrogen receptor alpha to estrogen-responsive elements. J Biol Chem 285:2676-2685.
21. Bourdeau V, et al. (2004) Genome-wide identification of high-affinity estrogen response elements in human and mouse. Mol Endocrinol 18:1411-1427. (Pubitemid 38692179)
22. O'Brien JE, et al. (2006) Estrogen-induced proliferation of uterine epithelial cells is independent of estrogen receptor alpha binding to classical estrogen response elements. J Biol Chem 281:26683-26692. (Pubitemid 44401877)
23. Gibson MK, et al. (1991) The mechanism of ICI 164,384 antiestrogenicity involves rapid loss of estrogen receptor in uterine tissue. Endocrinology 129:2000-2010.
24. Dauvois S, Danielian PS, White R, Parker MG (1992) Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci USA 89:4037-4041.
25. Scully KM, et al. (1997) Role of estrogen receptor-alpha in the anterior pituitary gland. Mol Endocrinol 11:674-681. (Pubitemid 27225295)
26. Maurer RA, Notides AC (1987) Identification of an estrogen-responsive element from the 5′-flanking region of the rat prolactin gene. Mol Cell Biol 7:4247-4254. (Pubitemid 17166403)
27. McInerney EM, Katzenellenbogen BS (1996) Different regions in activation function-1 of the human estrogen receptor required for antiestrogen- and estradiol-dependent transcription activation. J Biol Chem 271:24172-24178. (Pubitemid 26327401)
28. McDonnell DP, Clemm DL, Hermann T, Goldman ME, Pike JW (1995) Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol Endocrinol 9:659-669.
29. Sinkevicius KW, et al. (2008) An estrogen receptor-alpha knock-in mutation provides evidence of ligand-independent signaling and allows modulation of ligand-induced pathways in vivo. Endocrinology 149:2970-2979. (Pubitemid 351724534)
30. Danielian PS, White R, Hoare SA, Fawell SE, Parker MG (1993) Identification of residues in the estrogen receptor that confer differential sensitivity to estrogen and hydroxytamoxifen. Mol Endocrinol 7:232-240. (Pubitemid 23066866)
31. Penot G, et al. (2005) The human estrogen receptor-alpha isoform hERalpha46 antagonizes the proliferative influence of hERalpha66 in MCF7 breast cancer cells. Endocrinology 146:5474-5484. (Pubitemid 41653062)
32. Jakacka M, et al. (2002) An estrogen receptor (ER)alpha deoxyribonucleic acid-binding domain knock-in mutation provides evidence for nonclassical ER pathway signaling in vivo. Mol Endocrinol 16:2188-2201. (Pubitemid 35155533)
33. Glidewell-Kenney C, et al. (2007) Nonclassical estrogen receptor alpha signaling mediates negative feedback in the female mouse reproductive axis. Proc Natl Acad Sci USA 104:8173-8177. (Pubitemid 47185894)
34. Börjesson AE, et al. (2011) Roles of transactivating functions 1 and 2 of estrogen receptor-alpha in bone. Proc Natl Acad Sci USA 108:6288-6293.